BioSpace News Archive

Company’s clinical and commercial manufacturing capabilities to be showcased during BIO-Europe® , November 11-13 in Hamburg, Germany

BioSig Technologies, Inc., a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, announced that the Company further expanded its Investor Relations team by appoining Ms. Sasha Gentling, CFA as Director of Business Development and Investments.

Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its third quarter 2019 financial results for the period ended September 30, 2019, on Tuesday, November 12, 2019, after the market closes.

Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that Fred Colen, CEO of Neovasc, will be participating in two institutional investor conferences in November.

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and nine months ended September 30, 2019.

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the three and nine months ended September 30, 2019.

Today reported financial results for the third quarter ended September 30, 2019 and corporate highlights.

GAAP net income of $3.9 million and diluted GAAP earnings per share of $0.32

In a Human Mass Balance study, etrasimod metabolism demonstrated no major metabolites

Conference Call to be Held on November 12, 2019